TITLE

New melanoma drug requires gene mutation test

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
October 2011
SOURCE
American Journal of Health-System Pharmacy;10/1/2011, Vol. 68 Issue 19, p1764
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports the FDA approval of vemurafenib, marketed as Zelboraf by Roche Group's Genentech, for use against melanoma having a V600E genetic mutation in the gene that encodes the protein kinase BRAF. The article mentions that a study shows that vemurafenib helps improve overall survival in patients, with a risk of cutaneous squamous cell carcinoma in 26 percent of treated patients. It is mentioned that the drug is available only through specialty pharmacies.
ACCESSION #
65580784

 

Related Articles

  • KIT Genetic Mutation in a Melanoma Patient. Chandra, Pranil K. // Personalized Medicine in Oncology;Apr2014, Vol. 3 Issue 2, p82 

    No abstract available.

  • Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma. Acosta, Andres Martin; Kadkol, ShriHari S. // Archives of Pathology & Laboratory Medicine;Nov2016, Vol. 140 Issue 11, p1290 

    * The mitogen-activated protein kinase (MAPK) signaling pathway is a cascade of protein kinases that act in a sequential and predominantly linear fashion, albeit displaying some cross talk with other signaling cascades. Mutations in proteins integral to the MAPK signaling pathway are present in...

  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Johannessen, Cory M.; Boehm, Jesse S.; Kim, So Young; Thomas, Sapana R.; Wardwell, Leslie; Johnson, Laura A.; Emery, Caroline M.; Stransky, Nicolas; Cogdill, Alexandria P.; Barretina, Jordi; Caponigro, Giordano; Hieronymus, Haley; Murray, Ryan R.; Salehi-Ashtiani, Kourosh; Hill, David E.; Vidal, Marc; Zhao, Jean J.; Xiaoping Yang; Alkan, Ozan; Sungjoon Kim // Nature;12/16/2010, Vol. 468 Issue 7326, p968 

    Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an...

  • Biological insights into BRAFV600 mutations in melanoma patient. Improta, Giuseppina; Pelosi, Giuseppe; Tamborini, Elena; Donia, Marco; Santinami, Mario; De Braud, Filippo; Fraggetta, Filippo // OncoImmunology;Aug2013, Vol. 2 Issue 8, p1 

    The article discusses the role of BRAF gene mutations in patients with melanoma. Evidence from studies conducted suggested that BRAF mutations are unlikely to occur as homozygous alterations in a sample of patients with melanoma, with gene amplification contributing to mask the heterozygous...

  • Mutations of the BRAF gene in human cancer. Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian // Nature;6/27/2002, Vol. 417 Issue 6892, p949 

    Discusses a study which investigated BRAF genes somatic missense mutations in malignant melanomas. Mutations of genomic DNA from human cancers; Biological effects of cancer gene mutations; Methodology and results.

  • Failure to Detect Differences in Proliferation Status of Nevi from CDKN2A Mutation Carriers and Non-Carriers. Florell, Scott R.; Boucher, Kenneth M.; Holden, Joseph A.; Meyer, Laurence J.; Samlowski, Wolfram E.; Cannon-Albright, Lisa A.; Zone, John J.; Leachman, Sancy A. // Journal of Investigative Dermatology;Feb2002, Vol. 118 Issue 2, p386 

    Describes a study which tests the hypothesis that carriage of a CDKN2A mutation results in a higher proliferative status in nevi taken from carriers of the mutation relative to noncarrier family member controls. Relationship between the proliferation status of melanocytic lesions and CDKN2A...

  • Lack of TTC4 Mutations in Melanoma. Irwin, Nicole; Walker, Graeme; Hayward, Nicholas // Journal of Investigative Dermatology;Jul2002, Vol. 119 Issue 1, p186 

    States that no chromosome 1p tumor suppressor gene candidate associated with the development of a significant proportion of a particular cancer type such as melanoma has been identified. Focus on a gene called TTC4, a member of a family of genes that contain tetratricopeptide repeat motifs;...

  • Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase. Morcinek, Jessica C.; Weisser, Christin; Geissinger, Eva; Schartl, Manfred; Wellbrock, Claudia // Oncogene;3/7/2002, Vol. 21 Issue 11, p1668 

    Presents a study that examined the consequences of Xiphophorus melanoma receptor kinase (Xmrk) induced signal transducers and activators of transcription (STAT) 5 signaling. Background on STAT; List of STAT involved in the signaling of receptor tyrosine kinases; Role of STAT5 in the signal...

  • CDKN2A Germline Mutations in U.K. Patients with Familial Melanoma and Multiple Primary Melanomas. MacKie, Rona M.; Andrew, Nicola; Lanyon; Connor // Journal of Investigative Dermatology;Aug98, Vol. 111 Issue 2, p269 

    We report six of 16 U.K. melanoma families and two of 17 patients with multiple primary melanomas and a negative family history who have between them four different functionally damaging mutations of the CDKN2A (p16) gene: an Arg 24 Pro substitution in exon 1 in one family, a stop codon at codon...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics